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Abstract 
RNA molecules such as antisense RNA, hammerhead ribozyme, and siRNA, are now 
known to be capable of being potent regulator of gene expression, rather than a mere 
messenger between DNA and protein. The applications of these RNA molecules 
contribute significantly in the functional genomics research of post-genomic era by 
silencing target gene expression at RNA level. In vitro active hammerhead ribozymes 
that cleaved GFP and Elfin RNA in vitro were successfully constructed. Those in 
vitro active hammerhead ribozymes were found to be useful as tools for testing their 
in vivo activities. Green Fluorescence Protein (GFP) was used as a reporter to 
monitor in vivo activities of the anti-GFP ribozymes in a bacterial system, in which 
no in vivo activity of the ribozyme was detected. To study and compare the gene 
silencing effect of the anti-Elfm ribozyme, antisense RNA and siRNA, these RNA 
molecules were transiently expressed in a muscle cell line, C2C12. The antisense 
RNA and siRNA were designed such that they target the same site of the anti-Elfm 
ribozyme. However, no decrease in the Elfin RNA level was detected by the action of 




(ribozyme)，短片段干擾RNA (siRNA) •這些RNA分子的應用爲後基因組學 
(Post-Genomics)時代的基因功能硏究作出明顯的貢獻• 
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Chapter 1 Introduction 
Having the grand Human Genome Project completed, one of the tasks of biologists is 
to study the functions of genes. Functional studies are conducted usually by reverse 
genetics approach, i.e. the effect of knocking out or silencing the gene of interest on 
cells or animal models, which is compared with normal ones. With the recent 
advancement of RNA discoveries/technologies, it is easier to silence any gene of 
interest. Hence, RNA as a molecular tool to inhibit gene expression may make great 
contribution to the functional studies in the post-genomic era. The following is an 
overview of recent development in RNA technologies. 
1.1 Ribozymes 
RNA was once regarded as a mere messenger between DNA and proteins. Thanks to 
the revolutionary discovery of catalytic RNAs in 1980's, the term 'Ribozyme" was 
coined to refer to the catalytic RNA. There are many different kind of ribozymes 
found in the nature. 
The first discovery of ribozymes was made by two separate scientists Cech (Kruger 
et al, 1982) and Altman (Guerrier-Takada et al, 1983) almost at the same time, and 
their discovery led them to the honour of the Nobel Prize. Ribosome was found to be 
a ribozyme too (Cech 2000), which signifies the importance of ribozyme in nature. 
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1.1,1 RNA world hypothesis 
Discovery of ribozyme casts new insight not only on RNA, but also on the origin of 
life. RNA world hypothesis was proposed. It claims that in some early stages of 
evolution, before DNA and protein took the roles of storing genetic information and 
catalysis respectively, RNA had been responsible for both roles. Though it is hard to 
trace back to this period, the RNA world hypothesis is backed by experimental 
evidence. In vitro evolution experiments have been done to generate ribozymes of 
various catalytic activities to test if the necessary reactions of life can be performed 
by ribozymes. From these experiments, ribozymes were found to be able to catalyze 
quite a wide range of chemical reactions (Bartel et al, 1999). The basic scheme of in 
vitro evolution is that, the desired ribozymes is enriched from a pool of random 
sequences by differential amplification, after several rounds of amplification, the 
population of the desired ribozyme is greatly enriched and finally screened out 
(Wilson et al, 1999). As the RNA world hypothesis is adopted as the mainstream, 
some scientists even conceived a minimal ribo-organism such that the genetic 
material and the enzymes of which are RNA in nature (Bartel et al, 1999). 
2 
1.1.2 Hammerhead ribozyme 
Hammerhead ribozyme, a Mg2+ ion dependent metalloenzyme, can specifically 
cleaves target RNA whenever there is a NUX triplet on the target (N is any of the 
four nucleotides, U is uridine, X is adenine or uridine or cysteine but not guanosine). 
Its secondary structure is shown in the Fig. 1.1 
Stem III Stem I 
5’ NUX  
3'-NNNNNNNA NNNNNNNN-5' 
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Figure 1.1 Schematic Diagram of hammerhead ribozyme. 
The lower strand is the hammerhead ribozyme while the upper strand is the target 
RNA. The stem-loop II is the catalytic domain such that some sequences are 
conserved in order to render the ribozyme active, mutation of any one of those will 
render the ribozyme inactive. 
Since stem-loop II is responsible for the catalytic domain, we can direct the ribozyme 
cleavage by designing two appropriate annealing arms that target to any sequence 
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containing the NUX triplet, but it was recently reported that sequence elements 
outside the hammerhead ribozyme catalytic core enabled its intracellular activity 
(Khvorova et al, 2003). 
1.1.3 Applications of hammerhead ribozymes 
Numerous successful reports have demonstrated that hammerhead ribozymes can be 
used as molecular tools to inhibit gene expression. For example, ribozymes was 
shown to cleave the bcr/abl mRNA intracellularly (Lange et al, 1993); transgenic 
mice were produced by using ribozyme technique (Larsson et al, 1994); and the 
practicability of using hammerhead ribozyme in gene therapy, e.g. AID, was studied 
(Macpherson et al, 1999). 
1.1.4 Allosteric ribozymes widen the applications of ribozymes. 
In light of the fact that most of the protein enzymes are allosteric, scientists wanted 
to see if ribozymes can be modulated allosterically. The first allosteric ribozyme was 
a combination of a ribozyme with an ATP-binding aptamer, such that its activity can 
be modulated by varying ATP concentration (Tang et al, 1997). Since then, many 
different allosteric ribozymes saw the light, such as Cobalt ion responding 
(Seetharaman et al, 2001), oligonucleotide responding (Kuwabara et al, 1998)， 
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protein responding (Atsumi et al, 2001), and even ribozymes showing cooperative 
binding (Jose et al, 2001). With recent advancement of allosteric ribozyme, some 
novel biochip systems based on ribozymes were proposed (Marshall et al, 1999; 
Seetharaman et al, 2001), and there were suggestions that it might be used as a 
molecular hardware for biological computing (Jose et al, 2001) and also as a tool to 
detect the presence or absence of the analytes by transgenic organisms (Breaker 
2002). Post-transcriptional modification of protein can also be monitored by 
allosteric ribozymes (Vaish et al, 2002) 
1.1.5 ribozyme screening system 
There is no general rule to predict whether a ribozyme will be active in vivo. The first 
attempt to select for active ribozymes was reported by Lieber et al. (1995) They 
constructed an in vitro ribozyme screening system such that a pool of ribozymes of 
different specificities were used to cleave the target RNA in vitro, and the position of 
cleavage was then identified by RT-PCR of the cleavage products (Lieber et al, 1995). 
However, the in vitro active ribozymes identified by this method may or may not be 
in vivo active after all. An in vivo screening system is therefore preferred. 
An in vivo hairpin ribozyme screening system in mammalian cells was reported by 
Beger et al. (2001). A ribozyme library was introduced into human ovarian cancer 
5 
derived cells which stably expressed enhanced green fluorescence protein under the 
control of BRCAl promoter. Any increase in green fluorescence signal implied the 
BRCAl expression was up-regulated. Id4 was identified as a regulator of BRCAl 
expression (Beger et al, 2001). To our knowledge, there was no report on the 
development of a hammerhead ribozyme screening system in bacterial system. 
\ 
6 
1.2 Other RNA as gene silencing agents 
1.2.1 RNAi 
RNA interference (RNAi) refers to a phenomenon of sequence specific gene 
silencing due to the intervention of double-strand RNA, it was first discovered in C. 
elegans (Fire et al, 1998). RNAi was observed later in plants like A. thaliana, fungi 
like N. crassa, mouse embryonic stem cells, oocytes, and early embryos (Hutvagner 
et al, 2002). It was suggested that RNAi might descend from ancient antiviral 
protection mechanism in animals and plants (Grant 1999; Li et al, 2002). 
Mechanism of RNAi 
Although the mechanism of the action of RNAi has not been thoroughly revealed so 
far, a general model was proposed to explain it. The Fig. 1.2 shows the proposed 
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Fig. 1.2 Proposed mechanism of RNA interference 
This proposed mechanism involves an ATP dependent enzyme, Dicer, to generate 
small interfering RNA (siRNA), which is a short RNA duplex of 21-25nt originated 
from the original dsRNA. A dsRNA may be generated by RNA-dependent RNA 
polymerase (RdRp) followed by priming of the siRNA. Numerous siRNA in 
exponential scale are generated by Dicer. The siRNA may in turn activate 
RNA-induced silencing complex (RISC) that degrades the mRNA. But recent reports 
stated that RNAi mechanism may not involve RdRp. (Stein et al, 2003; Schwarz et al, 
2002). Stein et al reported that in mammalian oocytes, the use of a RNA synthesis 
inhibitor, cordycepin, did not prevent double strand RNA from targeting to 
endogenous mRNA, which indicated that RdRp may not be involved in mammalian 
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pathway (Stein et al, 2003). This discrepancy means that the RNAi mechanism is 
still not fully understood, but the above mechanism may give a rough sketch of it. 
Applications of RNAi 
In the functional genomics era, knocking out target gene is an ideal approach to study 
gene function, and so RNAi is intriguing. RNAi can be triggered by siRNA, so 
scientists make use of siRNA to disrupt gene expression. siRNA is preferred to 
dsRNA because of its small size, 21-25 nt, hence, convenient manipulation. Many 
reports showed that the result of gene silencing by siRNA was promising, e.g. in 
neurons (Krichevsky et al, 2002), and it worked in transgenic mice and rats too 
(Hasuwa et al. 2002). 
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1.2.2 Antisense RNA 
Antisense RNA refers to the RNA complementary to the sense strand of an mRNA. It 
was first discovered in 1981 by two separate groups (Tomizawa et al, 1981; 
Stougaard et al, 1981). Nearly all naturally occurring antisense RNAs were 
characterized in bacteria, with a few exceptions in eukaryotes (Brantl 2002). It is 
known that antisense RNA block protein translation by binding to its target mRNA, 
but the exact mechanism of the process is not unveiled. 
Application of antisense RNA 
Antisense RNA can work as small as 8 nucleotides (Fakler et al, 1994) and hence 
convenient to handle. It is used in disrupting gene expression in cellular level as early 
as 1987 (Heikkila et al. 1987). There were transgenic organisms produced by 
antisense RNA technology, such as the Flavr Savr tomato, the shelf life of which was 
extended by disrupting the expression of a ripening-responsible enzyme 
polygalacturonase. 
10 
1.3 Project overview 
The term "ribozyme" was used throughout the thesis to refer to hammerhead 
ribozyme unless otherwise stated. In my M. Phil project, gene specific hammerhead 
riboyzmes were designed, and their in vitro and in vivo activities were tested. 
1.3.1 Construction of anti-GFP ribozymes and their in vitro and in vivo activities 
In this project, seven anti-GFP ribozymes and a control ribozyme were designed. The 
in vitro activities of those ribozymes to cleave GFP RNA were tested. GFP, as a 
commonly used reporter gene, was chosen to be a marker for testing the in vivo 
activities of the ribozymes. We tested the activities of those ribozymes in vivo in 
bacterial system by observing the green fluorescence of the bacterial clones. Four in 
vivo systems were attempted for the testing of ribozyme activities. In Chapter 3, we 
would go into details about the construction of the anti-GFP ribozymes. 
1.3.2 Construction of anti-Elfin ribozyme and its application on gene silencing 
» 
study 
We tried to study the biological function of a functionally uncharacterized gene, Elfin, 
a 36kDa protein, suspected to be related to cytoskeleton and heart development 
(Kotaka et al, 2001). Anti-Elfin ribozyme and its control were designed. The in vitro 
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activities of the ribozyme and its control were tested. Based on the in vitro active 
anti-Elfm ribozyme, antisense RNA and siRNA were designed that targeted to the 
same position as the ribozyme's cleaving site. To check if antisense RNA, ribozyme 
and siRNA can exhibit any gene silencing effect, they were transiently expressed in 
mammalian myoblast C2C12 cell line. In Chapter 4，we would go into details about 
the construction of anti-Elfin ribozyme. 
12 
Chapter 2 Material and Methods 
2.1 Cloning techniques 
All oligonucleotides were ordered from Invitrogen Life Technologies. All the 
sequencing services were provided by either the service team of Department of 
Biochemistry, CUHK or Tech Dragon Ltd. 
2.1.1 Polymerase Chain Reaction (PGR) 
Reactions were performed in a volume of 25|LI1. Pfu DNA polymerase (Promega) was 
used. The sequence of reaction mix was prepared as follows: 
Sterile dHzO: ( 2 0 . 5 - X ) | L I 1 
lOx reaction buffer: 2.5|a.l 
dNTP: (2.5 mM each nucleotides) 0.5|il 
Forward primer: (1 OOpmol/fil) 0.5|j.l 
Reverse primer: (100pmol/|il) 0.5|LI1 
Template DNA: X^il 
DNA polymerase: (4 U/)al) O.Sfil 
Total: 25)^ 1 
Specific thermocycling profiles were stated in their corresponding sections. 
2.1.2 Restriction digestion of DNA 
Appropriate restriction digestion of DNA was carried out in a volume of 20)^ 1 
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routinely in appropriate buffer. The reaction was performed with 10 U or 20 U of each 
enzyme at 37°C for 3 hours. The enzymes used for restriction digestion included Aflil, 
Barnm, Bgm, Dralll, EcoRI, Ncol, Psd, Sad, Sail’ Sfil, Xhol, Xbal. All those 
enzymes, as well as the buffers, were purchased from New England BioLabs Inc. The 
general reaction profile was shown: 
DNA: Xfil 
1 OX NEB Buffer: 2\x\ 
lOXBSA: 21^ 1 
Autoclaved dHjO: (16-X-0.5n) 
Enzyme(s): (0.5 x n) |j.l 
Total: 20 III 
(Where n was the number of enzymes used, for n >1) 
2.1.3 Ligation of DNA fragments 
Ligation reaction was performed in a volume of 20|J.1 at 14°C for 16 hours. T4 DNA 
ligase (40 U/^1) (New England BioLabs Inc.) was used with reaction buffer provided 
by manufacturer. A negative control was always included such that all the reaction 
conditions were the same except for the absence of the insert. For ligation of 
oligonucleotides, the oligonucleotides were mixed and denatured at 95°C for 5 
minutes, and then cooled to room temperature slowly for annealing. The reaction 
profile was as follows: 
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Digested vector: X|LI1 
Digested insert: Y|J.1 
lOX Ligation buffer: 2|LI1 
Ligase: l|al 
Autoclaved dHzO: 17-X-Y \x\  
Total: 20|il 
The volume of the insert was always at least twice that of the vector. 
2.1.4 Preparation of competent cells 
Escherichia coli strain DH5a or C41 was streaked from a frozen stock onto a LB agar 
plate for DH5a and incubated at 37�C for 14 to 16 hours. Single colony from the plate 
was inoculated in 5ml of LB medium at 37°C and swirling at 280 rpm until ODeoo 
reached 0.3 to 0.4. The culture was added to 100ml LB medium and it was shaken at 
37°C until OD600 reached 0.4 - 0.5 unit. The culture was then chilled on ice for 5 
minutes and then centrifliged at 5g for 10 minutes at 4°C. The bacterial pellet was 
resuspended in 40 ml RFl (Section 2.1.9) and then kept on ice for 5 minutes. The 
bacterial suspension was then centrifuged again at 5000 x g for 10 minutes at 4°C. 
The bacterial pellet was then resuspended in 4ml RF2 (Section 2.1.9) and kept on ice 
for 15 minutes. The cells were then aliquoted into 1.5ml microfuge tubes in 100|al per 
tube and frozen in liquid nitrogen. The cells were then stored at -70°C until use. 
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2.1.5 Transformation of competent cells 
The competent cells were quickly thawed. The entire ligation product (20|al) or 
plasmid (l)j.l) would be added into the thawed competent cells. The cell then stood on 
ice for 30 minutes. The tube was slightly heated at 42°C for 2 minutes. The tube was 
then incubated on ice for 10 minutes. For ligation product, 400|J.1 LB was added to the 
cells and incubated at 37�C shook at 250rpm for 45 minutes. The cell was then 
pelleted by centrifugation at 12000 x g at room temperature for 2 minutes and 
resuspended in 100|il of LB which was then spread to a 90-mm LB agar plate 
containing appropriate antibiotic. For plasmid DNA, the cells were diluted with 400|il 
of LB and 50|il of bacterial cells was spread to a 90-mm LB agar plate containing 
appropriate antibiotic. 
2.1.6 Gel Extraction 
Gel Extraction was done by Life Technologies CONCERT^^ Rapid Gel Extraction 
System and the provided protocol was modified as follows: 
The gel containing the DNA fragment was excised and placed into a 1.5-ml 
microcentrifuge tube. The gel slice was weighted and 30|al Gel Solubilization Buffer 
(LI) was added for every lOmg gel. The gel slice was then incubated at 50�C until the 
gel slice completely dissolved. The gel solution was transferred into the spin 
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cartridge, which was contained in a 2-ml wash tube. The mixture was then centrifuged 
at > 12000 X g for 1 minute. After the flow-through had been discarded, the cartridge 
was placed back into the 2-ml wash tube and 500)il of Gel Solubilization Buffer (LI) 
was added to the spin cartridge. The cartridge was incubated at room temperature for 
1 minute, and then was centrifuged at > 12000 x g for 1 minute. The flow-through 
was discarded. The cartridge was placed back into the 2-ml wash tube, 700|il Wash 
Buffer (L2) (containing ethanol) was added to the spin cartridge and incubated for 5 
minutes at room temperature. The cartridge was centrifuged at > 12000 x g for 1 
minute. The flow-through was discarded and the cartridge was centrifuged again for 1 
minute to remove residual wash buffer. DNA was eluted out by adding 35|j.l 
pre-warmed autoclaved dHzO directly to the center of the spin cartridge in a 1.5-ml 
recovery tube. The cartridge stood at room temperature for 1 minute, and then the 
cartridge was centrifuged at > 12,000 x g for 2 minutes. 
2.1.7 Plasmid preparation 
2.1.7.1 Mini scale plasmid preparation 
The preparation was done by Life Technologies CONCERTTM Rapid Plasmid 
Minipreps. Provided protocol was modified as follows: 
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A single colony was inoculated into 5ml LB and shook at 37�C, 250rpm, for 14-20 
hours. The LB medium was then thoroughly removed. Cell Suspension Buffer (Gl) 
(containing 170|ig/ml RNase A) of 250|il was added to the pellet and the cells were 
suspended until homogeneous. Cell Lysis Solution (G2) of 250)j.l was added and 
mixed by gently inverting the capped tube 5 times. It was then incubated at room 
temperature for 5 minutes. Neutralization Buffer (M3) of 350^1 was added afterwards 
and mixed immediately by inverting the tube five times. The mixture was centrifuged 
at > 12,000 X g for 10 minutes. The supernatant was loaded into the spin cartridge, 
which was already contained in a 2-ml wash tube. The cartridge was centrifuged at > 
12,000 X g for 1 minute and the flow-through was discarded. The cartridge was placed 
back into the 2-ml wash tube and 500|a.l Optional Wash Buffer (GX) was added to the 
spin cartridge. Then, the cartridge was incubated at room temperature for 1 minute 
and then centrifuged at > 12,000 x g for 1 minute. After the flow-through had been 
discarded, the cartridge was placed back into the 2-ml wash tube. Wash Buffer (G4) 
(containing ethanol) of 700|xl was added to the spin cartridge. The cartridge was 
centrifuged at > 12,000 x g for 1 minute. The flow-through was discarded. Next, the 
cartridge was placed back into the wash tube and centrifuged again at > 12,000 x g for 
1 minute to remove residual wash buffer. At last, the cartridge was placed into 1.5-ml 
recovery tube, pre-warmed 50)^ 1 autoclaved dHiO was added directly to the center of 
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the spin cartridge and was incubated at room temperature for 1 minute. Finally the 
plasmids were eluted out by centrifUgation at > 12,000 x g for 2 minutes. Plasmids 
were stored at -20°C. 
2.1.7.2 Medium scale plasmidpreparation 
The medium scale plasmid preparation was done by QIAGEN HiSpeed Plasmid Kit. 
Procedures and solutions were essentially those provided: 
A single colony of bacteria, which was on an LB agar plate with appropriate antibiotic, 
was inoculated to 3ml LB medium with appropriate antibiotic for 8 hours at 37°C 
shaking at 250rpm, then it was transferred into 120ml of LB medium containing 
appropriate antibiotic and incubated for 14 to 16 hours at 37°C shaking at 250rpm. 
Bacterial pellet was collected by centrifugation at 5g for 10 minutes at 4°C. The pellet 
was resuspended in 6ml Buffer PI (containing 100 |ag/ml RNase A). Then 6ml Buffer 
P2 was added to the suspension that stood in room temperature for 5 minutes. Chilled 
Buffer P3 of 6ml was then added, and the mixture was poured into the barrel of a 
capped QIAfilter Cartridge. After it had stood in room temperature for 10 minutes, the 
clear lysate was filtered out from the QIAfilter Cartridge and collected in a HiSpeed 
Midi Tip, which had been equilibrated by 4ml Buffer QBT just before. The clear 
I 
lysate was allowed to enter the resin of the HiSpeed Midi Tip by gravity flow, 
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followed by washing with 20ml Buffer QC. The DNA was eluted with 5ml Buffer QF， 
and then precipitated by adding 3.5ml room temperature isopropanol and stood in 
room temperature for 5 minutes. After QIAprecipitator Midi Module had been 
attached to the outlet of a 20ml syringe, the eluate/isopropanol mixture was loaded 
into the 20ml syringe and eluate was filtered out. 2ml 70% ethanol was added the 
syringe to wash the QIArecipitator and then filtered out. The QIAprecipitation was 
air-dried by pressing air through the QIAprecipitator quickly and forcefully. The 
outlet nozzle of the QIAprecipitator was dried to prevent ethanol carryover. The 
QIAprecipitation was attached to a 5ml syringe, and the DNA was eluted by 1ml 
autoclaved dHaO. The eluate was then re-loaded to the 5ml syringe to elute the DNA 
from QIAprecipitator for a second time. The plasmids were stored at -20°C. 
2.1.8 DNA agarose gel electrophoresis 
1% (w/v) agarose gels were prepared by dissolving appropriate amount agarose into 
Ix TAE buffer containing 0.5 |Lig/ml ethidium bromide. DNA samples were mixed 
with 6X loading buffer (Section 2.1.9). Gel electrophoresis was performed at constant 
voltage of 100 V in a gel tank containing appropriate volume of Ix TAE. 
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2.1.9 Buffer and reagents 
Competent cells preparation 
RFl: 30 mM KAc, 100 mM RhCh, 10 mM CaClz, 50 mM MnCh, 15% glycerol. pH 
was adjusted to 5.8 by HAc. No back titration. It was sterilized by filtration through 
0.2 )am filter. 
RF2: 10 mM MOPS, 75 mM CaC12, 10 mM RbC12, 15% glycerol. pH was adjusted 
to 6.5 with KOH. It was sterilized by filtration through 0.2 |j,m filter. 
Buffer for agarose gel electrophoresis 
TAE (Tris-acetate-EDTA), 50x stock solution 
242 g/L Tris base 
57.1 ml/L glacial acetic acid 
37.2 g/L Na2EDTA.2H20 
The volume was made up to IL with Nanopure H2O 
6x DNA agarose gel loading buffer 
0.25% (w/v) bromophenol blue 
40% (w/v) sucrose 
60 mM EDTA(pH8.0) 
It was stored at 4°C. 
Medium for bacterial culture 
LB medium 
20g LB (Luria-Bertani) broth powder 
The volume was made up to IL Nanopure H2O. The medium was sterilized by 
autoclave. 
LB agar plate 
20g LB broth powder 
15gagar 
The volume was made up to IL with Nanopure H2O and sterilized by autoclave. 
The cooled liquid medium was poured into 90mm Petri dishes with appropriate 
antibiotics or inducers and allowed to gel. 
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2.2 In vitro cleavage of target RNA by ribozyme 
2.2.1 In vitro transcription of target RNA and ribozyme 
In vitro transcription of RNA was done by Promega RiboMAX^"^ Large Scale RNA 
Production Systems - T7 according to the provided protocol. The transcription was 
done to generate radioactive GFP, Elfin or the size markers mRNA or non-radioactive 
RNA of the ribozymes. The reaction profile was shown. 
DNA template: (-0.5 |ig) Xjil 
5X transcription buffer: 4)il 
rNTPs(25mM each ribonucleotides): 6|al 
Enzyme Mix: l\x\ 
[a-32p]-GTP for radioactive labeling: 1 f^ l 
DEPC treated HzO: l\x\ (radioactive) or 8fil 
Total 20|^ 1 
The reaction mixture was incubated in 37°C for 2 hours, followed by adding l|uil 
DNase incubating in 37°C for 30 minutes. 
2.2.2 Purification of transcription products 
Due to the size difference of transcription product, the ribozymes were purified by 
phenol/chloroform extraction and ethanol extraction, while the other RNAs were 
purified by lithium chloride precipitation. 
The ribozymes obtained after transcription was dissolved in 580|LI1 DEPC treated H2O, 
and 600fil phenol/chloroform/isoamyl alcohol (25:24:1) (Invitrogen Life 
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Technologies) was added and mixed vigorously. The mixture was then centrifuged at 
12000 X g, 4°C for 2 minutes. The aqueous phase was transferred to a tube, which 
contained 500)^1 chloroform, and mixed vigorously. The mixture was centrifiiged at 
12000 X g, 4°C for 2 minutes. The aqueous phase was then transferred to a tube, 
which contained 40|il 3M sodium acetate, and then 1ml ice-cold absolute ethanol was 
added. The mixture was stored at -70�C for 1 hour for precipitation and then 
centrifuged at 12000 x g, 4°C for 5 minutes. The supernatant was discarded and the 
pellet was washed by 1ml 70% ethanol, followed by centrifugation at 12000 x g, 4 � C 
for 5 minutes. The RNA pellet was air-dried at 42�C for 2 minutes and finally 
dissolved in 500|al DEPC treated H2O. The RNA was then loaded to the Sample 
Reservoir of Amicon® Microcon® YM-3，3000NMWL. The RNA was then 
concentrated by centrifugation at 12000 x g at 4 � C until the sample volume reached 
50|il. 450|il DEPC treated H2O was added to dilute the 50|al RNA sample, and again 
the sample was concentrated by centrifugation at 12000 x g at 4°C until the sample 
volume reached SOfil. The RNA was stored at -80°C. 
The transcription product of GFP, Elfin and size markers was purified by lithium 
chloride. DEPC treated H2O of 5[x\ was added to the entire transcription product 
followed by 25pi 5 M lithium chlorides. After the mixture had been stored at -20°C 
for 30 minutes for RNA precipitation, it was centrifuged at 12g, 4°C for 30 minutes. 
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The RNA pellet was washed with 1ml 70% ethanol, and centrifuged at 12000 x g，4°C 
for 10 minutes. Then, the pellet was air-dried at 42°C for 2 minutes and dissolved in 
20fal DEPC treated H2O. 
The integrity of the RNA was tested by urea-polyacrylamide gel electrophoresis 
before proceeding to the cleavage reaction. 
2.2.3 Ribozymatic cleavage reaction 
0.5^1 radioactively labeled target RNA was mixed with 8.5|al ribozyme in l^il lOX 
ribozyme cleavage buffer (Section 2.2.10) at 37°C for 1 hour. 
2.2.4 Preparation of RNA size marker templates 
Two size markers were originally cloned by colleagues. The Hepatitis B Virus X 
protein (HBx) in pGBKTT was digested by Sail restriction enzyme and the 
Thermococus Ribosomal Protein (TRP) in pRSETA was digested by £coRI restriction 
enzyme, and the restriction digestion products were purified by gel extraction. The 
transcript of HBx and TRP were 542 nucleotides and 375 nucleotides in size 
respectively. 
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2.2.5 Urea-polyacrylamide gel electrophoresis 
Urea-polyacrylamide gel is a denaturing gel usually used for separating RNA 
according to their sizes. After the two glass plates and spacers for electrophoresis had 
been cleaned in DEPC-treated water, the smaller glass plate was wiped with 
repel-silane (dimethyldichlorosilane solution 2% (w/v) in 1,1,1 -trichloroethane) using 
paper towel. The glass plates were assembled with spacers and held by clippers. 
8M urea solution was prepared by dissolving 14.4g ultra-pure urea into around 10ml 
DEPC-treated H2O. After 5X TBE (Section 2.2.10) of 3ml had been added, 30% 
acrylamide (29% acrylamide, 1% bis-acrylamide) of 5ml was add for casting 5% gel, 
and 11ml was added for casting 11% gel. DEPC-treated H2O was then added to final 
volume of 30ml. 10% ammonium persulfate of 150 p-l was added, followed by 3|al 
TEMED. The gel solution was immediately mixed and poured to the glass assembly 
with caution to avoid gas bubbles. A Comb of 24 wells was inserted. The assembly 
was then positioned horizontally and stood in room temperature until use. 
After the gel had been polymerized, the urea gel was pre-run in 0.5X TBE under 
constant power 5W for 30minutes. The RNA samples were incubated in 65�C for 5 
minutes with RNA loading buffer (Section 2.2.10). Just before the samples loading, 
the wells were washed. The samples were loaded with caution to avoid spilling. The 
gel was run at constant power 20W. 
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After the electrophoresis had finished, the assembly was disbanded. The gel was 
transferred to a Whatman 3mm filter paper and enclosed with plastic wrap. 
Autoradiography was done to detect bands 
2.2.6 Autoradiography 
Kodak BioMax Films were used to capture the image. The film was exposed within a 
cassette at room temperature for one overnight or longer. The exposed films were 
developed with Kodak GBX developer, fixed with Kodak GBX fixer for 5 minutes. 
The developed films were then rinsed with tap water and air-dried. 
2.2.7 Buffer and reagents 
DEPC treated H2O 
1ml ultra pure Diethylpyrocarbonate was dissolved in 2L Nanopure H2O 
DEPC treated H2O Water was always used in all RNA buffer 
Urea gel electrophoresis 
5X TBE buffer 
54g Tris base 
27.5g Boric acid 
20ml 0.5M EDTA (pH 8.0) 
Dissolved in IL DEPC treated H2O 
RNA loading buffer 
95% (v/v) deionized formamide 
0.025% (w/v) bromophenol blue 
5mM EDTA (pH 8.0) 
0.025% (w/v) SDS 
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Ribozyme cleavage reaction 
lOX Ribozyme cleavage buffer 
200mM MgCh 
500mM Tris-Cl (pH 8.0) 
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2.3 Detection of cellular RNA expression 
RT-PCR Detection 
2.3.1 RNA Extraction 
TRIZOL® (Invitrogen Life Technologies) was used to extract the total RNA of the 
® 
mammalian cells. Samples were homogenized in 1ml TRIZOL and incubated in 
room temperature for 5 minutes, followed by addition of 200|il chloroform. Having 
the samples vigorously shaken for 15 seconds, they stood in room temperature for 2 
minutes. The samples were then centrifuged at 12000g for 15 minutes at 4°C. The 
aqueous phase was transferred into a fresh tube that already contained 500|j.l 
isopropanol. RNA was precipitated in room temperature for 10 minutes and followed 
by centrifugation at 12000 x g for 10 minutes at 4°C. Supernatant was removed, and 
the RNA pellets were washed by 70% ethanol, followed by centrifugation at 7500 x g 
for 5 minutes at 4°C. The pellets were air-dried at room temperature for 5 minutes, 
and dissolved in \5\i\ DEPC treated H2O. The integrity of the RNA was checked by 
1% agarose gel electrophoresis in ethidium bromide added RNA loading buffer. The 
RNA samples were stored at -80°C until use. 
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2.3.2 DNase I Treatment 
The RNA sample was first treated with DNase I to remove genomic DNA 
contamination. The reaction profile is shown: 
RNA: _ 
lOX Transcription buffer: 2.5)il 
DEPC treated H2O: _ 
DNasel: 0.5)^1 
Total: 25 111 
The reaction mixture was incubated at room temperature for 15 minutes. Having 1 p,l 
EDTA added, the DNasel was inactivated by incubating the sample at 65°C for 10 
minutes, followed by putting the sample on ice for 2 minutes. 
2.3.3 Reverse Transcription 
The RNA sample thus treated was ready for reverse transcription reaction (Invitrogen). 
The reaction profile is shown: 
RNA (2|ag): X|Lil 
Primer: 2.5^1 
DEPC treated H2O: (50-X-2.5)  
Total: 50\i\ 
The reaction mixture was heat to 65°C for 5 minutes denaturation. Then the following 
reaction mixture was prepared: 
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5X Synthesis buffer: 4|j.l 
O.IMDTT: l|Lil 
DEPC treated H2O: l|il 
RNase out: 1 fil 
lOmMdNTP: 2^1 
Reverse Transcriptase: Ijil 
Total: _ 
The above lO^il reaction mixture was added to the 50|J.1 RNA samples, and incubated 
at 55°C for 1 hour, followed by heat inactivation at 85°C for 5 minutes. RNase H of 
IpJ was added to the sample, which was then incubated at 37°C for 20 minutes. The 
cDNA thus produced was stored at -20°C until use. 
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2.4 Mammalian cell culture techniques 
C2C12 which is a mouse muscle myoblast cell line used in the following experiments. 
2.4.1 Transfection into mammalian cells 
LipofectAMINETM Reagent, PLUS Reagent (Invitrogen Life Technologies) was used 
for transfection. 
Day 1: Around 1.1-3.3 x 10^ cells were seeded per well in a 6-well plate in 3 ml of 
the appropriate complete DMEM medium (Dulbecco's modified Eagle's medium). 
The cells were incubated at 37�C in a CO2 incubator until the cells were 50-80% 
confluent for 18-24 hours. 
Day 2: The cells were ready for transfection. Plasmid of Ijag was diluted into lOOjxl 
plain DMEM medium, then 6|J1 Plus Reagent was added and incubated at room 
temperature for 15 minutes. At the same time, 4|LI1 LipofectAMINE™ Reagent was 
diluted into lOOjul plain DMEM medium, mixed and incubated at room temperature 
also for 15 minutes. After incubation, the Plus Reagent - plasmid complex was mixed 
with the prepared LipofectAMINE^'^ Reagent, and incubated at room temperature for 
15 minutes to allow DNA-liposome complexes to form. During the complex 
formation, the cells were washed with IX PBS and 800|il plain DMEM medium was 
added per well. The 200|al plasmid-liposome complexes were added to each well after 
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incubation. The plasmid-liposome complexes were allowed to transfect the cells at 
37°C at 5% CO2 for 5 hours. To maximize cell growth, the liposome containing 
medium was replaced with 2ml complete DMEM medium or horse serum DMEM 
medium for induction of differentiation. Those media contained 600|ng/ml G418 for 
selection against non-transfected cells. The cells were then incubated for 48 hours at 
37°C in a CO2 incubator. 
Day 4: The cells were harvested such that RNA was extracted for analysis and the 
numbers of cells were counted. 
2.4.2 Counting of number of cells 
Two days after transfection, the cells were treated with 500ul trypsin, incubated at 
37°C for 5 minutes, and then SOO i^l complete DMEM medium was added. 20|al cell 
was mixed with 20|^1 2X Trypan Blue Stain 0.4%. The number of cells was counted 
by heamocytometer. The cell density was calculated by the equation: average number 
o f cells X 1 0 ^ ^ x 2 . 
2.4.3 Buffer and reagents 
Complete DMEM medium 
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10% v/v Fetal Bovine Serum (FBS) and 1% v/v Penicillin -Streptomycin (PS) was 
added to DMEM medium. 
Horse serum DMEM 
2% v/v horse serum and 1% v/v Penicillin -Streptomycin (PS) was added to DMEM 
medium for C2C12 differentiation induction. 
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Chapter 3 Construction of anti-GFP ribozymes 
and their in vitro and in vivo activities 
3.1 Introduction 
3.1.1 Objectives 
We aimed (1) to obtain anti-GFP ribozyme constructs that are active in vitro, and 
then, (2) to test if the anti-GFP ribozymes constructed in vivo active, to serve for the 
development of a screening system for ribozymes. 
3.1.2 Why anti-GFP ribozyme? 
Ribozymes, as gene silencing agents, have shown promising results. However, 
designing a ribozyme that is active in vivo remains to be a trial-and-error process, in 
which no general rule is known. Many efforts have been made [e.g. in vitro ribozyme 
screening system (Lieber et al, 1995), hairpin ribozyme screening system in 
mammalian cells (Beger et al, 2001)] in developing screening systems to identify 
ribozymes that are active in vivo. To our knowledge, a hammerhead ribozyme 
screening system in a bacterial system has not been reported. Bacterial system offers 
several advantages, such as ease of handling and well-established techniques for 
gene expression. 
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A reporter gene is required to monitor the in vivo activities of ribozymes in a 
screening system. GFP is chosen as the reporter in this study. It offers several 
advantages: (1) easy detection - green fluorescence can be observed by naked eyes; 
(2) well established techniques for detection - GFP has been extensively used as 
reporter in many other applications (e.g. sub-cellular localization of proteins and 
protein-protein interactions by Fluorescence Resonance Energy Transfer techniques); 
(3) high-throughput screening - cells can be sorted by flow cytometry according to 
their fluorescence signals. 
To develop a ribozyme screening system, we first construct anti-GFP ribozymes that 
are active in vitro and then we test the in vivo activities of the anti-GFP ribozymes 
using an E. coli system. 
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3.2 Construction of anti-GFP ribozymes that are active in 
vitro 
Seven anti-GFP ribozymes and one control ribozyme were designed. Ribozymes and 
GFP RNA were produced by in vitro transcription and mixed for cleavage. The 
results were analyzed in urea-polyacrylamide gel electrophoresis. We have 
demonstrated the successful in vitro cleavage of the GFP RNA by ribozymes. 
3.2.1 Design of the anti-GFP ribozymes 
GFPuv used in this study is a mutant GFP from pGLO (BioRad), the fluorescence 
signal of which is 18 times higher than that of wild-type. There are 2 criteria for 
selecting a ribozyme targeting site: (1) the existence o fNUX triplet for cleavage (N 
stands for A, U，C, G; X stands for A, U, C, but not G). In this project, only the GUC 
or AUC motifs were chosen, because they are the motifs that show the strongest 
cleavage signal; (2) the chosen target sites are not involved in complicated secondary 
structure; they are best located at open loop structure (Tabler et al’ 1997). 
The ORF of the GFP was predicted by the computer software BioEdit (version 5.0). 
GFP ORF ofpGLO was shown in the Appendix. There exist 18 GUC or AUC motifs 
in the GFP ORF. Among the 18 GUC/AUC motifs, 7 of them are located in open 
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loop structure predicted by the program "RNA structure" (Figure 3.1). As a result, 
hammerhead ribozymes that target to these 7 sites were designed (Table 3.1). All the 
ribozymes, with a catalytic domain of 22 nucleotides, possess 2 annealing arms each 
of 8 nucleotides that are complementary to the GFP mRNA. The annealing arms of 
the ribozymes were only specific to GFP but not other bacterial gene. In addition, a 
control ribozyme that does not target to any GFP sequence was also constructed. 
I ummm-
Ribozymes Sequence Cleaving The NUX 
pos i t ion triplet 
GRz-39 S'-AGAAUUGGCUGAUGAGnCCGAAAGGCCGAAACAACUCC-B' 39 GUC 
GRz-299 5 '-CUUUGAAACUGAUGAriGCCGAAAGGCCGAAAUAUAGUG-3， 299 AUC 
GRz-486 5'-UUAGCUUUCUGAUGAGGCCGAAAGGCCGAAAUUCCAUU-3' 486 AUC 
GRz-550 5'-AUUUUGUUCUGAUGAGnCCGAAAGGCCGAAAUAAUGGU-3' 550 AUC 
GRz-582 5'-GGUAAAAGCUGAUGAGGCCGAAAGGCCGAAACAGGGCC-3' 582 GUC 
GRz-608 S'-AUUGUGUCCUGAUGArir.CCOAAAGGCCGAAACAGGUAA-3' 608 GUC 
GRz-617 5'-AAAGGGCACUGAUGAGGCmAAAGGCCGAAAUUGUGUC-3' 617 AUC 
GRz-Con 5'-GCCACCCACUGAUGAGGCCGAAAGGCCGAAAGCCAAGU-3' Nil (control) Nil (control) 
immrnrn mmm 
Table 3.1 Sequence of anti-GFP ribozymes. The underlined nucleotides represent 
the catalytic domain, while the rest represent the annealing arms. The cleaving 
position in the GFP mRNA commenced from the AUG start codon. Only GUC and 
AUC in the GFP mRNA were chosen for the NUX triplets for ribozymatic cleavage. 
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The target sites of the ribozymes are located at positions across the entire sequence of 
GFP mRNA (Figure 3.1). The ribozymes were cloned into an expression vector for 
endogenous expression in bacterial cells. Eight pairs of DNA oligonucleotides, 
encoding the 8 ribozymes, each of 50 nucleotides, were ordered. Two compatible 
ends, Xba\ and BamHI of the ribozyme DNA were generated by annealing a pair of 
complementary oligonucleotides. An Ndel site for the ribozymes, except an EcoRL 
site for GRz-582, was introduced to facilitate screening of positive clones. The 
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Figure 3.1 Predicted secondary structure of GFP ORF. This is the predicted 
secondary structure generated by the computer software "RNA structure" 
(http://ma.chem.rochester.edu/RNAstructure.html). The arrows mark the target sites 
of the anti-GFP ribozymes, and also the start and end of the GFP transcript. 
5 • -CT A GA CAT AT GG-3 • 3 • -T GTATACCCTAG-5' 
The region in green is the Xbal compatible end 
The region in yellow is the ribozyme-encoding sequence 
The region in brown is the Ndel restriction site 
The region in blue is the flawH丨 compatible end. 
Figure 3.2 Schematic diagram of the ribozyme encoding pair of oligonucleotides. 
Ndel site was introduced to facilitate the screening during subcloning of ribozymes. 
The ribozyme was cloned in between Xbal and BamUl site of pET3d, such that the 
ribosome binding site, which may sterically hinder the cleavage activities of the 
ribozyme, was removed. 
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3.2.2 Construction of DNA templates for ribozyme in vitro transcription 
Preparation of DNA templates for in vitro transcription of ribozyme 
To facilitate in vitro transcription of ribozyme, a short DNA fragment (Figure 3.3) 
containing the T7 promoter sequence was inserted into pUC19 vector. Three unique 
restriction sites were also included to facilitate cloning and screening of the ribozyme 
oligonucleotides. The resulting plasmid, pUC-linker (Figure 3.4 A), was confirmed 
by DNA sequencing. 
5 • - G A T C T T A A T A C G A C T C A C T A 1 A (^ � T C T A G A G A C 1 ( � G A GT A G G A T C C C T GC A - 3 ’ 
3 ’ - A A T T A T G r T G A G 1 G A T A T C A G A T C T C T (.i . � .� �t T ' A T C C T A G G G - 5 ’ 
The region in green is the fig/II compatible end 
The region in blue is the T7 promoter 
The region in dark brown is the Xbal restriction site 
The region in light brown is the Xhol restriction site 
The region in pink is the fia/wHI site 
The region in purple is the Pstl compatible end 
Figure 3.3 Introduction of a T7 promoter and restriction sites into pUC 19. The 
sequence shown above, which has BglU and Pstl sticking ends, was cloned into 
pUC19 in between the BamUl and Pstl site. The downstream sequence of T7 
promoter was the restriction sites {Xbal and BamUl) for ribozymes cloning. The 
original site on pUC19 was destroyed after ligation. 
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The ribozyme oligonucleotides were cloned into the pUC-Linker in between the Xbal 
and the BaniRl sites. The modified plasmids were named as pUC-Rz (Figure 3.4 B). 
After confirmed by DNA sequencing, the plasmids were linearized by BamRl 
digestion and purified by gel extraction for in vitro transcription. 
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Figure 3.4 Cloning of pUC- linker and pUC-Rz 
Lane 1: Uncut pUC-Linker 
Lane 2: Xhol cut pUC-Linker 
Lane 3: Uncut pUC-Rz 
Lane 4: Ndel cut pUC-Rz 
Lane M: X Hind III Marker 
The original pUC19 plasmid was double-digested by Pstl and 5amHI. The 
oligonucleotides encoding for the multiple cloning sites was cloned into digested 
pUC19. The presence of din Xhol site indicated that the linker sequence was 
successfully cloned into pUC-Linker (A, lane 2). (B) The ribozyme encoding 
nucleotides were cloned into the pUC-Linker digested by Xbal and BamYil. Ndel 
digestion of the plasmid released a short band about 300bp, which mark the cloning 
• of pUC-Rz (B, lane 4). � 
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Preparation of templates for in vitro transcription of GFP 
The GFP template for the in vitro transcription of GFP RNA was prepared by PCR of 
the GFP from pGLO using pfu DNA polymerase (Figure 3.5). AT7 promoter was 
introduced upstream of the GFP start codon by the forward primer GFPinf and the 
reverse primer GFPinr. The PCR product was purified by gel extraction for in vitro 
transcription. 
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Figure 3.5 PCR preparation of GFP template for in vitro transcription 
Lane 1: PCR in the presence of pGLO 
Lane 2: -ve control 
Lane M: X Hind III Marker 
PCR was performed using primer GFPinf and GFPinr. The thermocycling profile of 
this PCR reaction was 94°C denaturation for 5 minutes, then 30 cycles of 94°C for 1 
minute, 59°C for 1 minute and 72°C for 1.5 minute. After 30 cycles, the PCR product 
was incubated at 72°C for 7 minutes. The distinct band in Lane 1 showed that the 
GFP was successfully amplified. 
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3.2.3 GFP RNA was successfully cleaved by ribozymes 
The GFP RNA was transcribed and labeled radioactively. The GFP RNA was mixed 
with the ribozymes and the result was analyzed in urea- polyacrylamide gel 
electrophoresis. The expected band pattern of the cleavage products was illustrated in 
Figure 3.6. 
The clear bands demonstrated that six ribozymes cleaved the GFP RNA (Figure 3.7). 
The smaller cleavage products were resolved by 9% polyacrylamide gel, it showed 
that GRz-550, GRz-582, GRz-608, GRz-617 were active in vitro (Figure 3.7 A). The 
5% polyacrylamide gel showed GRz-299, GRz-486, GRz-550, GRz-582 were active 
in vitro (Figure 3.7 B). 
The sizes of the cleavage products of GRz-39 were 39nt and 678nt, which were too 
small and too large for detection, though there existed a weak band as shown in the 
figure, we could not tell whether this ribozyme was active in vitro or not. 
In summary, we have obtained at least 6 in vitro active ribozymes, and 1 inactive 
control ribozyme. 
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Ribozyme Expected size of cleavage 
products (nucleotides) 
mm GRz-39 39 + 678 
_ GRz.299 299 + 418 
GRz-486 486 + 231 
_ GRz-550 550+ 167 
• GRz-582 582 + 135 
GRz-608 608 + 109 
_ GRz-617 617 + 100 
GRz-Con 717 (no cleavage) 
Figure 3.6 Schematic diagram of the pattern of the cleavage products. Due to the 
size difference of cleavage products, the expected band pattern cleaved by different 
anti-GFP ribozymes is shown. 
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(A) 8M urea 9% polyacrylamide gel (B) 8M urea 5% polyacrylamide gel 
Figure 3.7 In vitro cleavage of GFP by ribozymes 
Lane M: Size Markers 
Lane 1-8: GFP + Ribozymes 
The GFP RNA and ribozymes were prepared and mixed as described. The reaction 
mixtures were then analyzed in 8M urea 5% or 9% polyacrylamide gel. The cleavage 
products were marked by the arrows. It showed that cleavage occurred at lane 2，3，4, 
5 (B), which meant GRz-299, GRz-486, GRz-550, GRz-582 were active in vitro. The 
other gel showed that cleavage occurred at lane 4, 5, 6，7 (A), which meant that 
GRz-550, GRz-582, GRz-608, GRz-617 were active in vitro. The size markers were 
unresolved in 9% acrylamide. We suspected the band marked by the arrow in lane 1 
of panel A was the cleavage product of GRz-39, though the signal was very weak to 
be confirmed. We concluded that almost all ribozymes (GRz-39 in doubt) cleaved the 
GFP RNA. 
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3.3 In vivo activities of anti-GFP ribozymes 
3.3.1 Design of systems that detected anti-GFP ribozyme activities in vivo 
No report has demonstrated the construction of an efficient hammerhead ribozyme 
screening system in bacterial system. As the in vitro active anti-GFP ribozymes were 
constructed, their in vivo activities were tested. GFP was first cloned in a bacterial 
expression vector; meanwhile the in vitro active ribozymes were cloned into another 
vector. The GFP construct and the ribozymes construct were co-transformed into 
bacteria and upon induction, with the ribozyme cleaving activities, the clones showed 
no green fluorescence. Clones that showed green fluorescence might imply the lack 
of in vivo activities. Figure 3.8 shows the schematic representation of the 
experimental design. 
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Figure 3.8 Schematic representation of the experimental plan. We planned to 
construct 2 plasmids, one of which expressed GFP, while the other expressed 
ribozyme. Having the 2 plasmids transformed and RNA expression induced, the 
clones would not show green fluorescence if the clones expressed active ribozymes 
that cleaved the GFP mRNA. On the contrary, the inactive ribozyme would render 
the clone green fluorescence because of the expression of intact GFP mRNA. We 
could tell the activities of ribozyme by naked eyes observation of fluorescence signal 
and hence it would be convenient and efficient to screen out the active ribozyme. 
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3.4 The first trial - system a 
As we have proved the in vitro activities of the ribozymes, we proceeded to construct 
an in vivo system, initially, the system a. The basic scheme of the screening system a 
is shown in Figure 3.9. 
广 J V GFP 、 ( i C - i ^ V 
pGLO pACYC-Rz 
y ^ chiQramp_icoi ^ 
Figure 3.9 Schematic representation of system a. The GFP was originally in 
pGLO, under the control of P B A D promoter, which was in turn controlled by amC 
and the GFP expression was induced by arabinose. On the other hand, the ribozymes 
were cloned into pACYCl 84 plasmid (pACYC-Rz) under the control of T7 promoter 
and their expressions were driven by IPTG. The transformed bacterial cells were 
selected by ampicillin in pGLO and chloramphenicol in pACYC184. The pl5A 
replication origin ofpACYC184 is compatible with the pBR322 replication origin of 
pGL. With the 2 antibiotics resistance markers and these replication origins, the 
co-transformed bacterial cells are selected and the expression of GFP and ribozyme 
are induced 
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To individually control the expression of GFP and ribozymes, they were induced by 
2 different inducers. The expression of ribozyme was driven by a T7 promoter which 
does not exist in normal pACYC184, the ribozyme gene was therefore cloned 
downstream a T7 promoter in pET3d. Afterwards, the T7 promoter together with 
ribozymes was cloned into pACYC184. The pGLO and the ribozyme construct were 
co-transformed into bacterial cells to check the efficacy of this system. 
3.4.1 Cloning of ribozymes into pACYC184 
The oligonucleotides encoding the ribozymes were first cloned into the pET3d vector 
(Figure 3.10). Positive clones were finally confirmed by DNA sequencing. The 
pET3d with ribozymes inserts was named pET-Rz. The ribozymes insert together 
with the T7 promoter on the pET-Rz vector were then subcloned to pACYC184, a 
vector that contains the chloramphenicol resistance gene and a replication origin 
compatible with that of pGLO (Figure 3.9). A DNA fragment containing the 
ribozyme from pET-Rz was amplified by PGR using pfu DNA polymerase. The 
forward primer was p3dRzf while the reverse primer was p3dRzr. The PGR products 
were cloned to pACYC184 (Figure 3.11). Positive clones were confirmed by DNA 
sequencing, the plasmid obtained was named pACYC-Rz. 
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Figure 3.10 Cloning of pET-Rz 
Lane 1: uncut pET-Rz 
Lane 2: Nde\ cut pET-Rz 
Lane M: XVHind III Marker 
The oligonucleotides encoding the ribozymes were cloned into pET3d. Positive 
clones were screened by Ndel digestion (or EcoRl in case of GRz-582). The 
linearization of the plasmid showed the cloning of ribozyme into pET3d, since there 
, is no Ndel site in normal pET3d. 
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Figure 3.11 Cloning ofpACYC-Rz 
Lane M: XHind III Marker 
Lane 1: uncut pACYC-Rz 
Lane 2: EcoRl cut pACYC-Rz 
After PCR of the ribozyme ofpET-Rz, the PCR products were digested by Bglll, 
while the pACYCl 84 vector was digested by BamUl. The PCR products were cloned 
into the digested pACYC184, since Ba??iRl and Bglll were compatible. The 2 bands, 
each of about 2000bp, released by EcoRl digestion marked the cloning of ribozyme 
into pACYC184, because of the EcoRI site of ribozyme and the inherent £coRI site 
ofpACYC184. 
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3.4.2 IPTG interfered with GFP Expression 
IPTG was found to interfere with GFP expression. E. coli strain C41 was first 
transformed with pGLO on a LB A plate, and 1% (w/v) arabinose was added for the 
induction of GFP expression. Arabinose was added to induce the expression of araC 
protein, which in turn activated the P B A D promoter for transcription of G F P gene. A 
colony that showed green fluorescence under ultraviolet radiation was picked for the 
preparation of C41-pGL0 competent cells. The pACYC-Rz was transformed into the 
C41-pGL0 on a LB AC plate, with 1% (w/v) arabinose and 0.4mM IPTG added to 
drive expression of GFP and ribozymes. Two additional controls were done such that 
all experimental conditions were the same except that (1) pACYC-Rz was not 
transformed, and (2) pACYC-Rz and IPTG was not added for the second control. 
Under ultraviolet radiations, we observed that all the colonies of the ribozyme 
constructs did not show green fluorescence (Figure 3.12. C). However, green 
fluorescence was observed in the first control (Figure 3.12. A), but green 
fluorescence did not show in the second control (Figure 3.12. B). Such observations 
suggested that the use of IPTG alone interfered with the expression of the GFP. IPTG 
may interfere with the arabinose metabolic pathway and there might not be 
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Figure 3.12 IPTG interfered with GFP expression. pGLO and pACYC-Rz were 
sequentially transformed into E, coli C41 strain, and selected with LB AC plates. GFP 
expression was induced by l%(w/v) arabinose. Two controls were performed such 
that only pGLO was transformed without (A) and with (B) addition of 0.4mM IPTG. 
Expression of GFP was suppressed by 0.4mM IPTG (B) without the presence of any 
ribozyme construct, which was the same case as the co-transformation of pGLO and 
pACYC-Rz. Such observations suggested that system a was not informative on 
reporting in vivo activities of anti-GFP ribozymes. 
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3.5 The second trial - system p 
In l ight o f the IPTG interference of system a, we tried to clone the GFP into pET3d 
vector in order to avoid the complication of two different inducers, i.e. IPTG was 
used to drive expression o f both GFP and ribozymes. Figure 3.13 shows the 
schematic representation o f the system (3. 
The GFP was cloned into a modified pET3d vector instead of the pGLO. Then we 
transformed both pET-nGFP and pACYC-Rz into bacterial cells to check the efficacy 
o f the system. 
, k S ^ GFP H y ( 
pET-nGFP pACYC-Rz 
^ • • ^ ^ • • • ― ^ Chbramphenicol , 
Figure 3.13 Schematic representation of system P. In contrast wi th system a 
(Figure 3.9), the GFP was cloned in a modified pET3d vector, and GFP expression 
was controlled by T7 promoter (pET-nGFP), which was the same as that o f 
pACYC-Rz. pET3d also contains a pBR322 replication origin and an ampici l l in 
resistance gene, which means that pET3d is compatible wi th pACYC-Rz and also the 
selection o f co-transformed bacterial cells is possible. This system eliminated the use 
o f two inducers that might interfere wi th the expression of the two genes. 
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3.5.1 Insertion of new multiple cloning sites into pET3d 
To facilitate further cloning on pET3d, we designed new multiple cloning sites and 
the schematic diagram is shown in Figure 3.14. A pair of oligonucleotides encoding 
the designed multiple cloning sites were ordered and cloned into pET3d (Figure 
3.15). Positive clones were confirmed by DNA sequencing. This modified pET3d 
was named pET-neu. 
5'-CT AGAAATTAAGA AGGAGAT AT AGUC CA 1' (“‘、. <. u ( ( G CC C A C C A C GT G CT CGA G C A T AT G 
I TT A A T T C T T C C T C T A T A T i CGGl A ( ( ( , ( ( ( , t, C C. fi GT G GT G C A C GA G CT C GT A T A C -5’ 
The region in green is the Xba\ compatible end 
The region in blue is the SD sequence 
The region in orange is S/U restriction site 
The underlined region is Noll restriction site 
The region in purple is Dralll restriction site 
The region in red is Xho\ restriction site 
The region in brown is Ndel restriction site 
The region in yellow is the fiamHI compatible end 
Figure 3.14 Schematic diagram of the new multiple cloning sites of pET-neu. 
The sequence containing the cloning sites was cloned into the Xbal and BamEl sites 
of pET3d. These newly introduced restriction sites did not overlap with the existing 
restriction sites of pET3d. 
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Figure 3.15 Cloning of pET-neu 
Lane 1: uncut pET-neu 
Lane 2: SJTL cut pET-neu 
Lane 3: DralU cut pET-neu 
Lane 4: XIiol cut pET-neu 
Lane 5: Ndel cut pET-neu 
Lane M: X\Hind III Marker 
The oligonucleotides encoding for the multiple cloning sites was cloned into Xbal 
and BamHl digested pET3d vector. Positive clones were screened by the use of 4 
different restriction enzymes, which all linearized the plasmid. The figure 
demonstrated that the multiple cloning sites were successfully cloned. 
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3.5.2 Cloning of the GFP into pET-neu 
GFP was cloned into the Dralll sites of pET-neu, and there was no Dralll site in the 
GFP sequence. The GFP was amplified from pGLO by PGR using pfu DNA 
polymerase. The forward primer was GFPneuf, while the reverse primer was 
GFPneur and the thermocycling profile was exactly the same as Figure 3.5. The PGR 
products were cloned into pET-neu (Figure 3.16). Positive clones were confirmed by 
DNA sequencing. This plasmid was known as pET-nGFP. 
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Figure 3.16 Cloning of pET-nGFP 
Lane 1: uncut pET-nGFP 
Lane 2: DralW cut pET-nGFP 
Lane 3: DraWl cut pET-nGFP 
Lane M: MHind III Marker 
PGR for GFP amplification was performed as described. The PGR products were 
digested by DralW, followed by cloning to DralW digested pET-neu. Screening by 
DralW digestion was performed such that the release of a short band about 700bp, 
which matched the size of GFP PCR product, so GFP was cloned. 
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3.5.3 GFP Expression was interfered by the additional T7 promoter 
It was found that GFP expression was inhibited by the additional T7 promoters. E. 
coli strain C41 was transformed by pET-nGFP on a LB A plate containing 400|iM 
IPTG for induction of GFP expression. A colony that showed green fluorescence 
under ultraviolet radiation was picked for the preparation of C41-pETnGFP 
competent cells. C41-pETnGFP was then transformed by pACYC-Rz on a LB AC 
plate, with 0.4mM IPTG added to drive expression of both GFP and ribozymes. 
Controls were done such that all experimental conditions were the same except that (i) 
no pACYC-Rz transformed, (ii) an empty pACYC vector transformed (i.e. T7 
promoter cloned but no ribozyme cloned), (iii) pET-nGFP was transformed into E. 
coli strain BL21 pLysS to check if the pET-nGFP was compatible with pACYC 
vector. Under ultraviolet radiations, we observed that none of the colonies 
transformed with pACYC-Rz showed green fluorescence (Figure 3.17 C). However, 
green fluorescence was also not observed in the control experiment that had an 
empty pACYC-Rz transformed, i.e. a pACYC vector with a T7 promoter but without 
ribozyme (Figure 3.17 D). On the other hand, green fluorescence was observed in the 
colonies of the E. coli strain BL21 pLysS (Figure 3.17 E) (the plasmid pLysS is the 
same as an empty pACYC-Rz except it lacks the T7 promoter). Taken together, the 
presence of two T7 promoters on the two plasmids interfere with each other and 
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suppress the expression of GFP, which might be due to the competition of cellular 
resources for expression. In conclusion, we didn't find system p informative and 
hence sought for another approach. 
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Figure 3.17 Interference of GFP expression by the additional T7 promoters. 
pET-nGFP and pACYC-Rz were sequentially transformed into E. coli C41 strain, 
and selected with LB AC plates. GFP expression was induced by 0.4mM IPTG in (A). 
However, the transformation of a pET-nGFP and any pACYC vector containing a T7 
promoter (B, pACYC-conRzB; C, pACYC-Rz; D, pACYC-T7) resulted in no GFP 
expression in the presence of 0.4mM IPTG, suggesting the two T7 promoters on pET 
and on pACYC interfere with eah other. Green fluorescence was observed in 
colonies of E. coli strain BL21 (pLysS) (E), 
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3.6 The third trial - system 8 
In view of the problems encountered in system a and (3, we found that no matter the 
use of 2 inducers or 1 inducer to drive GFP and ribozyme expression, the systems 
were not informative on reporting the in vivo activities of ribozymes. Therefore, we 
tried to express the GFP and the ribozyme in cis, i.e. to clone and express the GFP 
and ribozyme in the same mRNA strand. In this system, we tried to clone the 
ribozyme upstream of the GFP. Figure 3.18 shows the schematic representation of 
design of system 5. 
The expression of ribozymes and GFP on the same mRNA strand eliminated the need 
to clone them into 2 different plasmids. Moreover, the ribozyme to substrate (GFP 
mRNA) ratio must be 1:1, while it was hard to estimate the ribozyme to substrate 
ratio in the previous systems. 
r^  
^ - B B H s U l GFP 
pET-RzfnGFP 
^ B B M B B m 
Figure 3.18 Schematic representation of system 5. We planned to clone the 
ribozyme upstream of the GFP, such that a chimera mRNA expressing the ribozyme 
and GFP was transcribed under the control of T7 promoter. 
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3.6.1 Insertion of a new cloning site into pET-neu 
We modified the upstream cloning region of pET-neu, while the cloning region of 
pET-neu as shown in Figure 3.14 was left untouched. A pair of oligonucleotides 
encoding the new cloning site was ordered such that it contained an AflW site for 
ribozyme cloning and a ribosome-binding-sequence for GFP expression. Figure 3.19 
shows the design of the cloning site. 
The pair of oligonucleotides encoding for the above sequence was cloned into 
pET-neu (Figure 3.20). Positive clones were confirmed by DNA sequencing. The 
f 
plasmid thus produced was named pET-fn. 
5 ' - C T A G A A A T A A T T T T G T T T A A C C T T A A G T T A A G A A G G A G A T A T A C 
T T T A T T A A A A C A A A T T GG A A I T ( A A T T C T r C C T CT A T A T G G T A C - 5 ' 
The region in green is the Xbal compatible end 
The region in orange is the AflW restriction site 
The region in blue is the SD sequence 
The region in pink is the Nco\ compatible end 
Figure 3.19 Schematic representation of the new cloning site of pET-fn. This new 
cloning site replaced the original sequence between Xbal and Ncol region ofpET-neu. 
The newly introduced AfRl restriction sites did not overlap with the existing 
restriction sites in pET-neu. We planned to clone the ribozymes into Xbal and AjRl 
sites, which was upstream of the GFP cloning site {Dralll). 
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Figure 3.20 Cloning of pET-fn 
Lane 1: uncut pET-fti 
Lane 2: AflW cut pET-fh 
Lane M: AAHind III Marker 
r 
The oligonucleotides encoding for the cloning site was cloned into pET-fii. Positive 
clones were screened by AJUl digestion. The plasmid was linearized as shown, it 
implied that the AJRl restriction site was cloned. 
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3.6.2 Cloning of GFP and ribozymes into pET-fn 
First, GFP was cloned into the Dralll sites of pET-neu. GFP was prepared by PCR 
from pGLO using primer GFPneuf and GFPneur, and the thermocycling condition 
was the same as that of Figure 3.5. The GFP PCR product was cloned to pET-fn 
(Figure 3.21). Positive clones were confirmed by DNA sequencing. This new 
plasmid was called pET-ftiGFP. 
Ribozymes were then cloned into pET-fnGFP. PCR was performed to amplify 
riboyzme from pET-Rz by pfu DNA polymerase using forward primer p3dRzX and 
reverse primer p3dRzA. The PCR products were then cloned upstream of the GFP of 
pET-fnGFP through Xbal and Aflll sites (Figure 3.22). Positive clones were 
confirmed by DNA sequencing. The new plasmid thus formed was named as 
pET-RzfnGFP. 
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Figure 3.21 Cloning ofpET-fnGFP 
Lane 1: uncut pET-fnGFP 
Lane 2: DralW cut pET-fiiGFP 
Lane M: X\Hind III Marker 
PCR for GFP amplification was performed as described. The PCR products were 
digested by Dralll, followed by cloning to Dralll digested pET-neu. Screening by 
Dra in digestion was performed such that the release of a short band about 700bp, 
which matched the size of GFP PCR product, so GFP was cloned. 
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Figure 3.22 Cloning of pET-RzfnGFP 
Lane M: AAHind III Marker 
Lane 1: uncut pET-RzfnGFP 
Lane 2: Ndel cut pET-RzfnGFP 
PCR for ribozyme amplification was performed as described. The PCR products 
were cloned into pET-fiiGFP by Xbal and 4/711. Positive clones were screened by 
Ndel digestions. There are 3 Ndel sites of pET-RzfhGFP, one of GFP, one of the 
ribozyme and one of multiple cloning sites of pET-neu. Ndel cut of the plasmid 
showed 2 small fragments, one of about 300bp and one of 500bp, indicated that the 
ribozyme was cloned into pET-fnGFP 
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3.6.3 Ribozyme sequence upstream of GFP interfered with GFP expression. 
E. coli strain C41 was transformed by pET-RzfhGFP on a LB A plate containing 
0.4mM IPTG for induction of GFP expression, as well as pET-fnGFP, which acted as 
a positive control. Presence of green fluorescence was observed under ultraviolet 
radiation. We observed that none of the colonies transformed with pET-RzfhGFP 
showed green fluorescence (Figure 3.23 C), as well as in the control ribozyme 
(Figure 3.23 B), while the colonies of pET-fnGFP (no ribozyme cloned) did show 
green fluorescence (Figure 3.23 A). Such observations indicated that the upstream 
ribozyme might somehow block the GFP expression. The ribozymes might be too 
close to the ribosome-binding-sequence and may fold into some compact structure 
that hinders ribosome binding. In conclusion, we didn't find system 5 informative 
and hence sought for another approach. 
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Figure 3.23 Ribozyme sequence upstream of GFP interfered with GFP 
expression. pET-fhGFP and pET-RzftiGFP were transformed into E. coli C41 strain, 
the former was a positive control. GFP expression was induced by 0.4mM IPTG in 
(A), but the GFP expression was inhibited in all the ribozyme constructs (C), as well 
as the by the construct expressing the control ribozyme (B). Such observation 
suggested that somehow the mere presence of the upstream ribozymes sequence, 
rather than the catalytic activities of ribozymes, silenced the GFP expression. System 
5 was therefore not informative 
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3.7 The fourth trial - system � 
We still tried to express the ribozyme and GFP in the same mRNA, in contrast with 
system 6, the ribozyme in this system was cloned downstream to the GFP. Figure 
3.24 is the schematic representation of the system co. 
J ^ - ^ I R I GFP - • ？ I K ^ 
pET-nGFPrRz 
Figure 3.24 Schematic representation of system We planned to clone the 
ribozyme downstream of the GFP, such that a chimera mRNA expressing the GFP 
and ribozymes was transcribed under the control of T7 promoter. 
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3.7.1 Insertion of new cloning sites into pET-neu 
We modified the downstream cloning region of pET-neu, while the cloning region 
upstream Xhol of pET-neu (Figure 3.14) was left untouched. A pair of 
oligonucleotide encoding the new cloning site was ordered such that it contained a 
Kpnl site and an AjRl site for ribozyme cloning. Figure 3.25 is the schematic diagram 
of new cloning sites. 
A pair of oligonucleotides encoding the above sequence was cloned into pET-neu 
(Figure 3.26). Positive clones were confirmed by DNA sequencing. The plasmid thus 
produced was named pET3d-nr. 
5 ' - 'I ( (i A c.T T A G G T A C C T G A C CT C T T A A GG 
^ A A T C C A T G G A C T G G A G A A T T C C C T A G - 5 ' 
The region in green is the Xhol compatible end 
The region in blue is the Kpnl restriction site 
The region in purple is the AjRl restriction site 
The region in red is the 5amHI restriction site 
Figure 3.25 Schematic representation of the new cloning sites ofpET-nr. The 
above DNA fragment replaced the original sequence between Xhol and BamYil of 
pET-neu (Figure 3.14). The newly introduced AflW restriction sites did not overlap 
with the existing restriction sites in pET-neu. We planned to clone the ribozymes into 
Xbal and AJRl sites, which was downstream of the GFP cloning site (Dralll). 
74 
1 2 3 M 
• 
Figure 3.26 Cloning of pET-nr 
Lane 1: Ajlll digested pET-nr 
Lane 2: Kpn\ digested pET-nr 
Lane 3: uncut pET-nr 
Lane M: XAHind III Marker 
The oligonucleotides encoding for the multiple cloning sites was cloned into 
pET-neu. Screening was done by AjRl and Kpnl digestion. The plasmid was as 
shown linearized by 4/711 and Kpnl digestions, the 2 restriction sites were cloned. 
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3.7.2 Cloning of GFP and ribozymes into pET-nr 
First, GFP was cloned into the Dralll sites of pET-neu. GFP was prepared by PGR 
from pGLO using primer GFPneuf and GFPneur, and the thermocycling condition 
was the same as that of Figure 3.5. The GFP PCR product was cloned to pET-nr. 
After transformation (Figure 3.27)，positive clones were confirmed by DNA 
sequencing. This new plasmid was called pET-nGFPr. 
Ribozyme was then amplified by PCR from pET-Rz by pfu DNA polymerase using 
forward primer p3dRzK and reverse primer p3dRzA. The ribozyme PCR products 
were then cloned downstream of the GFP of pET-nGFPr (Figure 3.28). Positive 
clones were confirmed by DNA sequencing. The new plasmid thus formed was 
named as pET-nGFPrRz. 
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Figure 3.27 Cloning ofpET-nGFPr 
Lane 1: uncut pET-nGFPr 
Lane 2: DraWl digestion of pET-nGFPr 
Lane 3: Dralll digestion of pET-nGFPr 
Lane M: MHind III Marker 
PGR for GFP amplification was performed as described. The PGR products were 
cloned into pET-neu by the restriction enzyme Dralll. Screening by Dralll digestion 
was performed such that the release of a short band about 700bp, which matched the 
. s i z e of GFP PGR product (Lane 2). 丨 
77 
1 2 M 
I 
Figure 3.28 Cloning of pET-nGFPrRz 
Lane 1: Nde\ cut pET-nGFPrRz 
Lane 2: Ndel cut pET-nGFPrRz 
Lane M: X\Hind III Marker 
PCR for ribozyme amplification was performed as described. The PCR products 
were cloned into pET-nrGFP by Kpnl and Aflll. Positive clones were screened by 
Ndel digestions. The presence of a short fragment about 600bp in lane 1 was due to 2 
Mdel sites, one inside the GFP and one inside the ribozyme. Lane 1 therefore marked 
the cloning of the ribozyme. 
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3.7.3 Anti-GFP ribozymes did not turn off green fluorescence of GFP 
E. coli strain C41 was transformed with pET-nGFPrRz on a LB A plate containing 
0.4mM IPTG for driving GFP expression. Presence of green fluorescence was 
observed under ultraviolet radiation. We observed that all the colonies of 
pET-nGFPrRz showed green fluorescence (Figure 3.29 A), as well as in the control 
ribozyme (Figure 3.29 B). A negative control was included to demonstrate the 
absence of green fluorescence (Figure 3.29 C), in which no IPTG was added. At last, 
the system co was informative, because the control ribozyme did not interfere with 
the GFP expression (Figure 3.29 B), while in previous systems the control ribozyme 
did interfered with GFP expression, but unfortunately the ribozyme could not turn off 
the green fluorescence signal. 
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Figure 3.29 Anti-GFP ribozyme did not turn off green fluorescence of GFP. 
pET-nGFPrRz were transformed into E. coli C41 strain. GFP expression was induced 
by 0.4mM IPTG in (A), but the GFP expression was also observed in the control 
ribozyme construct (B). A negative control (without IPTG) was performed to contrast 
the green fluorescence signal (C). Such observation suggested that the ribozyme 
construct fail to in vivo cleave GFP mRNA. 
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3.7.4 No in vivo cleavage of GFP RNA was detected 
RT-PCR was performed to detect whether the ribozyme cleaved the GFP in vivo or 
not. A control was included such that the pET-nGFPr was transformed to express 
only GFP, but not ribozyme. Bacterial RNA was extracted after 0.4mM IPTG 
addition for induction. After reverse transcription, the RNA samples were normalized 
by PGR of the bacterial 16S rRNA (Figure 3.30 A). PGR was performed to detect the 
expression level of GFP, since the intensities of the bands were identical, we 
concluded that down-regulation of GFP was not detected (Figure 3.30 B). Possible 
reasons of the absence of in vivo activities are discussed in Chapter 5. 
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(A) m U m H 10 cycles mn^ n^m^m ^  
(B) m m m ^ H 19 cycles 
H H ^ B I ^ ^ H H I H I H I 22 cycles 
Figure 3.30 RT-PCR showing no in vivo cleavage of GFP 
Lane C: control ribozyme 
Lane 1: GRz-39 
Lane 2: GRz-299 
Lane 3: GRz-486 � 
Lane 4: GRz-550 
Lane 5: GRz-582 
Lane 6: GRz-608 
Lane 7: GRz-617 
Lane G: GFP (without ribozyme) 
This figure shows there was no in vivo cleavage of GFP. The RNA samples were 
normalized by PCR of the bacterial 16S rRNA, which was not detected before the 
10出 cycle (A). PCR of the GFP mRNA was performed. PCR samples were taken at 
the 16th, 19th’ cycles. The GFP mRNA was not detected before the 1 c y c l e , 
and it was found that the intensities of all the bands were identical (B). It indicated 
that there was no in vivo cleavage of GFP in system co. 
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3.8 Summary 
1. According to the predicted secondary structure, we have designed 7 ribozymes that 
target open loops of GFP's transcript. At least six of them (GRz-299, GRz-486, 
GRz-550, GRz-582, GRz-608, GRz-617) could cleave the target RNA in vitro, and 
the control ribozyme did not have in vitro activitities. 
2. Four in vivo systems were constructed. System a , P，5 were not informative 
because green fluorescence was not observed in the control ribozyme. System co was 
informative, but the anti-GFP ribozyme failed to suppress the green fluorescence of 
the bacterial colonies. Lack of m vivo activities of ribozyme was confirmed by 
RT-PCR 
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Chapter 4 Construction of anti-Elfin ribozyme 
and its application on gene silencing study 
4.1 Introduction 
4.1.1 Objectives 
We aimed (1) to construct an in vitro active ribozyme; and (2) to study and compare 
the effect of using antisense RNA, ribozymes and siRNA in silencing gene 
expression of Elfin. 
4.1.2 Elfin 
Elfin was originally identified as a human 36 kDa protein (Kotaka et al, 1999). 
Based on the human Elfin, the mouse version was cloned (Kotaka et al, 2001). In this 
project, the mouse Elfin was studied. 
Elfin belongs to a member of the Enigma proteins family, also known as PDZ-LIM 
protein family, that was first identified in 1997 by Xia et al. Enigma proteins contain 
one to three LIM domains at the carboxyl terminal, and a PDZ domain at the amino 
terminal, while only one LIM domain exists in Elfm. The G-L of G-L-G-F signature 
of PDZ is replaced by P/S-W in Enigma proteins (Guy et al, 1999). 
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Elfin was found to express abundantly in heart, moderately in lung, spleen, testis, and 
skeletal muscles, and it expresses in mouse embryos as early as E7 (Kotaka et al, 
2001). Though the physiological functions of the members of Enigma protein family 
are not revealed, it was suggested that they might be the adapters between kinases 
and cytoskeleton (Nakagawa et al, 2000). Yet the mouse Elfin, like the human 
homologue, was believed to interact with a-actinin of skeletal muscle (Kotaka et al, 
2000). The mouse Elfin was found to localize at the actin stress fiber of myoblasts 
and it was suggested that Elfin might be important in myofibrillogenesis and heart 
development (Kotaka et al, 2001). The biological role of Elfin can be studied by 
silencing its expression at RNA levels by the recent development of RNA 
technologies. 
4.1.3 Experimental plan 
We defined a term "RNA tools" to collectively mean the antisense, ribozyme and 
siRNA. We first constructed anti-Elfm ribozyme that was active in vitro. Antisense 
RNA and siRNA that targets the same site of the anti-Elfm ribozyme were then 
designed. The gene silencing effects of the RNA tools were compared by monitoring 
the expression of Elfin in myoblast C2C12 cell line using RT-PCR. 
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4.2 In vitro cleavage of Elfin RNA by ribozyme 
We tried to obtain an in vitro active anti-Elfm ribozyme first. Ribozymes and Elfin 
RNA, which were produced by in vitro transcription, were mixed for cleavage; the 
results were analyzed in urea-polyacrylamide gel electrophoresis. We have 
successfully demonstrated the cleavage of Elfin RNA by the designed ribozyme. 
4.2.1 Design of anti-Elfin ribozyme 
The secondary structure of Elfin transcript was predicted by the computer software, 
RNA structure (version 3.6). The 258 '^' to the 276''' nucleotides of the Elfin ORF 
(5 '-GATTTGGTCTCCTCTAGTG) was chosen to study because this region met the criteria 
for the design of ribozyme and siRNA (for later experiment) that, there exist a GUC 
motif in the Elfin RNA for ribozyme cleavage, and this sequence was predicted not 
to be involved in complicated RNA secondary structures. The sequence of Elfin ORF 
is shown in the Appendix VI. 
Ribozyme was designed to target the GUC triplet of Elfin ORF at the 266^^ 
nucleotides. The ribozyme contained a catalytic domain of 22 nucleotides, and 2 
annealing arms each of 8 nucleotides complementary to the Elfin ORF, spanning 
from the 25S'*" to the 274^^ nucleotides. A control was included such that its sequence 
was the same as the active one, except for a G to A mutation in the catalytic domain 
that inactivates the ribozymes. The sequence was supposed to fold into a 
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hammerhead like structure as shown in Figure 4.1. The sequences are shown in Table 
4.1 
• Ribozyme 5'-ClJAGAGGACUGAUGAGGCCGAAAGGCCGAAACCAAAUC-3' 
Control ribozyme 5'-a)AGAGGACUaAUGAGGCCGAAAGGCCGAAACCAAAUC-3' 
Table 4.1 Sequence of the anti-Elfin ribozyme and control. The underlined region 
shows the catalytic domain and the small letter a in the control ribozyme shows the 
mutated nucleotide, which render the control ribozyme inactive. 
3,-CUAAACCA AGGAGAUC-5' 
A C 。 — 







Figure 4.1 Schematic diagram of secondary structure of hammerhead ribozyme. 
The catalytic core of the hammerhead ribozyme must properly fold into a 
hammerhead secondary structure to achieve catalytic function, the above shows the 
intact catalytic core of the active ribozyme, while mutation of a G to A at the marked 
position would render the ribozyme inactive, which is the designed control ribozyme. 
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4.2.2 Preparation of DNA template for in vitro transcription 
Two pairs of the ribozyme encoding oligonucleotides were ordered, 1 for the active 
ribozyme while the other for the inactive ribozyme. The design scheme was the same 
as Section 3.2’ except for the absence of the Ndel restriction site. The pairs of 
oligonucleotides were cloned into pUC-Linker (Section 3.2.2). Positive clones were 
confirmed by DNA sequencing. 
The Elfin RNA was originally cloned in pGBKT7 by colleagues, and it was 
linearized by Sail digestion for transcription and purified by gel extraction. 
4.2.3 Successful In vitro cleavage of Elfm by ribozymes 
The Elfm RNA was transcribed and labeled radioactively. Though the ribozymes 
were not radioactively labeled, a radioactive control was done to monitor the 
integrity of the RNA. The Elfm RNA was mixed with the ribozymes and the result 
was analyzed in 8M urea 5% polyacrylamide gel electrophoresis (Figure 4.2). The 
figure clearly demonstrated that the ribozyme we designed cleaved the Elfm RNA in 
vitro, while the control ribozyme was not active. 
In summary, we have successfully obtained an in vitro active anti-Elfin ribozyme, we 
could then proceed to in vivo system to study its gene silencing effect along with the 
antisense RNA and siRNA. 
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Figure 4.2 In vitro cleavage of Elfin by ribozyme. 
Lane 1: active ribozyme + Elfin 
Lane 2: inactive ribozyme + Elfm 
Lane 3: Elfin alone 
Lane M: Size markers 
The Elfm RNA and the ribozyme was mixed as described, the result was analyzed in 
8M urea 5% polyacrylamide gel. Only the active ribozyme cleaved the Elfm RNA, 
the expected size of the cleavage product was 335 and 715 nucleotides, the larger one 
matched the size marker, though the signal of the smaller one might be too weak to 
observe. The Elfm thus was cleaved by the ribozyme we designed. 
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4.3. In vivo gene silencing studies of RNA tools 
The secondary structure of Elfin transcript was predicted by the computer software, 
RNA structure (version 3.6). The 258^^ to the nucleotides of the Elfm ORF 
(5 ' - G A T T T G G T C T C C T C T A G T G ) , which was the same targeting region of ribozyme, was 
chosen to study because this region met the criteria for the design of ribozyme and 
siRNA. The RNA tools were cloned into pSilencer 1.0, which is a mammalian RNA 
expression vector, and the RNA tools were transiently expressed in the myoblast 
C2C12 cell line. Gene silencing effect of the RNA tools were detected by RT-PCR. 
4.3.1 Design of Antisense RNA 
Antisense RNA was designed to cover the range from the 258^^ to the 
nucleotides of the Elfm ORF, spanning 17 nucleotdies. The complementary copy, the 
sense strand, of the antisense was also included as a control, as well as a control of 
scrambled antisense sequence, which possess the same nucleotides composition as 
the antisense. This control sequence was found to be not complementary to any gene 
sequence by BLAST search. Both the controls were of 17 nucleotides in length. The 
sequences of the antisense and the 2 controls were shown in Table 4.2. 
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Antisnse 5'-CUAGAGGAGACCAAAUC-3' 
Sense (control) 5 '-GAUUUGGUCUCCUCUAG-3， 
Scrambled sequence (control) 一 5 ’ - U C G U A G U G U U C G A U C U C - 3 ’ ‘ 
Table 4.2 Sequence of the designed Elfin specific antisense RNA and controls 
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4.3.2 Design of siRNA 
siRNA was designed to target the Elfin ORF from the 258^^ to the nucleotides. 
Such position was chosen because (1) there exists an AA duplex sequence in the 
256th and 257* nucleotides, which is upstream of the target sequence, (2) the GC 
content of such sequence is 47%, while sequence of less than 50% GC content is 
believed to have a higher chance to induce RNAi phenomenon, (3) the region do not 
contains an inherent stretch of 4 or more thymine, which signals for the termination 
of RNA polymerase III. The design of siRNA was instructed by Ambion® website. 
The siRNA contained a sense strand targeting the 258^^ to the nucleotides of 
Elfin ORF, a complementary antisense strand, in between linked by a short sequence 
of 9 nucleotides for forming a hairpin structure, and a stretch of 6 uridine nucleotides 
was added to the 3’ end of the siRNA. A control was included such that it was same 
as the design of active siRNA, except for the scrambled sequence of the sense strand 
and antisense strands. The scrambled sequence was found to be not complementary 
to any other gene sequence by BLAST search. siRNA was supposed to fold into a 




Control siRNA 5'-GUUGGGCCUAUAACAUUAGUUCAAGAGACUAAUGUUAUAGGCCCAACUUUUUU-3‘ 
Table 4.3 Sequence of the designed Elfin specific siRNA and control The 
underlined sequence shows the sense strand and the antisense strand 
5， ^ 、 
UUUUUU ^ 
Figure 4.3 Schematic diagram of the secondary structure of the siRNA. The 
sense strand and the antisense strand, linked by a loop of 9 nucleotides, formed a 
stable hairpin structure with a stretch of poly U at the 3 ’ end. 
93 
4.3.3 Cloning of the RNA tools into pSilencer 
We aimed at delivering the RNA tools in vivo，therefore we cloned the RNA tools 
encoding oligonucleotides into a RNA expression vector for cellular transient 
expression. pSilencer 1.0 was purchased from Ambion®. This vector was especially 
designed for RNA expression, which was driven by a mouse U6 promoter. The RNA 
polymerase III promoter produces transcripts that are more defined in length than the 
mRNA transcribed by RNA polymerase II，which contains a poly-A tail. 
Eight pairs of DNA oligonucleotides, each encoding one RNA tool, were ordered and 
cloned. Positive clones were confirmed by DNA sequencing. The plasmid thus 
formed was named pSilencer-R. 
4.3.4 Cloning of a neomycin resistance gene into pSilencer-R 
Since the original pSilencer do not contain any selection marker for mammalian cells, 
a neomycin resistance gene was cloned so as to eliminate those non-transfected cells. 
A neomycin resistance cassette was amplified by PCR from a mammalian expression 
vector pIRES using forward primer Neof and reverse primer Neor. The PCR product 
was then cloned into the pSilencer-R (Figure 4.4). Positive clones were confirmed by 
DNA sequencing. Plasmid thus formed was named as pSilencer-Rneo. 
The efficiencies of the use of G418 in selecting transfected cells were estimated by 
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counting the cell number of (i) a control without transfection, (ii) a control that was 
transfected with empty pSilencer-Rneo (without RNA tools), (iii) cells that 
transfected by RNA tools cloned pSilencer-Rneo. 
The cell densities were respectively (i) 1.4 x 10^ (ii) 4.5 x 10^ (iii) 6.1 x 10^ these 
numbers meant, on average, the ratio of non transfected cell to transfected cell was 
about 1: 40，the error rate was about 2.5% (1/40), this small error rate would not 
affect the interpretation of the results of RT-PCR. 
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Figure 4.4 Cloning of a neomycin resistance marker into pSilencer-R 
Lane 1: uncut pSilencer-Rneo 
Lane 2: DraWl cut pSilencer-Rneo 
Lane M: X\Hind III Marker 
PCR was performed to amplify the neomycin resistance gene, the thermocycling 
profile was: 94°C denaturation for 5 minutes, and 30 cycles of 94°C for 1 minute, 
55°C for 1 minute and 72°C for 2.5 minutes. After 30 cycles, an additional period of 
72°C for 7 minutes was included. The PCR product was then cloned into pSilencer-R 
by Drain restriction enzyme, screening was done by Dralll, the release of a band 
about 1600bp matched the size of the PCR product, and hence the neomycin 
resistance gene was cloned. 
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4.3.5 Elfin RNA was not down-regulated 
C2C12 is mouse myoblast that can be induced to differentiate into myotube by 
starving the cells in minimal medium (DMEM with only 2% horse serum). It was 
known from colleague (Miss Yee-Man Lau) that Elfm expression reached maximum 
after 2 days differentiation. We would therefore test the effect of the RNA tools at 2 
different time point, (1)2 days after transfection for no induction of cellular 
differentiation, in other words, 0 day after induction of cellular differentiation; (2) 2 
days after induction of cellular differentiation. After RNA extraction and reverse 
transcription, cDNA amount was normalized by PCR of P-actin, and finally the 
expression level of Elfm was detected by PCR using forward primer Elfinf and 
reverse primer Elfinr (Figure 4.5). It was found that Elfm expression level was the 
same among samples transfected with different RNA tools at both day 0 (Figure 4.5a) 
and day 2 (Figure 4.5b) after induction of cellular differentiation. The reasons of the 
absence of in vivo activities of the RNA tools are discussed in Chapter 5. In 
conclusion, Elfm was not down-regulated by the RNA tools. 
\ 
97 
C 1 2 3 4 5 6 7 W 
(A) j H ^ m m m i l l ^ l 22 cycles 
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Figure 4.5a RT-PCR showing no down-regulation of Elfin RNA (Day 0) 
Lane C: Control vector (without insert) 
Lane 1: Sense 
Lane 2: Antisense 
Lane 3: Antisense control 
Lane 4: Ribozyme 
Lane 5: Control ribozyme 
Lane 6: siRNA 
Lane 7: Control siRNA 
Lane W: Control (without DNA transfection) 
RT-PCR was performed as described and the RNA samples were normalized by the 
amount of (3-actin. (A) PCR was performed for 22, 25 and 28 cycles. (3-actin was not 
detected before the 22"�cycle. (B) Elfm expression of 0 day after cellular 
differentiation induction (i.e. no differentiation induction) was detected by RT-PCR 
for 25 and 28 cycles. Elfm mRNA was not detected before the cycles. The 
intensities of the bands were almost the same in all the samples, which means there 
was no down-regulation of Elfm when cellular differentiations were not induced. 
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Figure 4.5b RT-PCR showing no down-regulation of Elfin RNA (Day 2) 
Lane C: Control vector (without insert) 
Lane 1: Sense 
Lane 2: Antisense 
Lane 3: Antisense control 
Lane 4: Ribozyme 
Lane 5: Control ribozyme 
Lane 6: siRNA 
Lane 7: Control siRNA 
Lane W: Control (without DNA transfection) 
RT-PCR was performed as described, the RNA samples were normalized by p-actin 
(A) PCR was performed for 22，25 and 28 cycles. P-actin was not detected before the 
22nd cycles. (B) Elfin expression of 2 days after cellular differentiation induction 
were detected by RT-PCR for 25 and 28 cycles. Elfin mRNA was not detected before 
the 25th cycles. The intensities of the bands were almost the same in all the samples, 




1. According to the predicted secondary structure, we have designed a ribozyme that 
cleaved the 266'^ nucleotides of the Elfin transcript. The active ribozyme was in vitro 
active, while the control ribozyme was inactive. 
2. Plasmids that encoded ribozymes, as well as antisense RNA and siRNA, were 
transfected into the muscle cell line C2C12. No down-regulation of Elfm expression 
was detected by RT-PCR at both day 0 and day 2 after induction of cellular 
differentiation. 
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Chapter 5 Discussions 
Anti-GFP and anti-Elfin ribozymes were active in vitro 
In my project, I have successfully established the in vitro cleavage system for 
ribozymes. Obtaining in vitro active ribozymes was an important step before 
studying their in vivo activities. We have demonstrated that at least 6 in vitro active 
anti-GFP ribozymes were obtained (Figure 3.7a and 3.7b), as well as 1 anti-Elfm 
ribozyme (Figure 4.2). 
Incomplete cleavage of the GFP and Elfin by their respective ribozymes was 
observed. The intensities of the cleavage products were relatively low, while the 
intensities of the GFP and Elfin transcripts remained high. It is quite common to 
observe incomplete cleavage reaction by ribozyme in vitro (for example, Kim et al, 
1999). Nevertheless, the results of in vitro cleavage experiment served as a proof that 
the designed ribozymes did have activities in vitro, before we tested them in in vivo 
systems. 
Ribozymes that were active in vitro do not have activities in vivo 
Although we have successfully constructed ribozymes that were active in vitro, they 
did not achieve the gene silencing effect in vivo. No suppression of green 
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fluorescence was observed when the ribozyme constructs were transformed into E. 
coli C41 strain (Figure 3.29). Absence of ribozymatic cleavage was further supported 
by RT-PCR (Figure 3.30). There are so many factors within in vivo bacterial system 
that may affect the ribozymatic cleavage, such as the binding of ribosome to the 
mRNA that prevents the GFP mRNA from cleaving by the ribozymes. This view is 
supported by a report, which stated that the ribozyme was active in a slow ribosome 
E. coli mutant, but not active in the wild type (Chen et al, 1997). Moreover, the low 
physiological concentration of Mg2+ ions (0.1- 0.3 mM) may affect the activities of 
the ribozyme, while that of in vitro cleavage was 20mM (Khvorova et al, 2003). 
Similarly, anti-Eflin ribozymes failed to down-regulate expression of Elfin in 
myoblast C2C12 in both day 0 and day2 after induction of cellular differentiation 
(Figure 4.5). Antisense RNA and siRNA targeting the same site of Elfin's transcript 
did not suppress the gene expression of Elfin (Figure 4.5). There were three 
possibilities to explain the absence of down regulation, (i) the RNA tools did not 
express, (ii) the RNA tools expressed but not active in vivo, (iii) the RNA tools 
expressed but the target sites were not responsive to the RNA tools, or (iv) the RNA 
tools expressed and the target sites were responsive, but the level down regulation 
was too trivial to observe. We tended to eliminate possibility (i) since expression of 
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the RNA tools from the pSilencer vector was well documented and we have followed 
the established procedures, and the use of neomycin enabled the selection of 
transfected cells. 
Incomplete in vivo cleavage may obscure phenotype observation 
The in vivo cleavage of the ribozyme may be incomplete like the situation of in vitro 
cleavage. The ribozyme may cleave only a portion of target mRNA, leaving the rest 
intact. If the turnover rate of the protein is low, the protein translated from the 
remaining intact mRNA may stay within the cell and exhibit its normal function, 
thereby rendering the phenotype of the cells indistinguishable from the control. This 
problem can be partly solved by using or engineering variants of GFP that have a 
shorter half-life in cells. 
How to design an in vivo active ribozyme is still not fully understood - an update 
on latest ribozyme research 
The stem loop II of the hammerhead ribozyme has long been considered as solely 
responsible for the activities, the 2 annealing arms did not contribute to catalytic 
activity, but there was report stating that the intracellular activity required sequence 
outside the stem loop II (Khvorova et al, 2003). Khvorova et al did not pinpoint what 
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sequence may contribute intracellular activities, but their discovery may shed new 
light on the studies of the hammerhead ribozyme catalysis, and also on the future 
design of hammerhead ribozymes. 
The target site of the ribozymes may not be accessible because of the compact 
folding of target RNA in vivo, there was report stating the RNA helicase associated 
ribozyme may cleave any mRNA regardless of the structure of the target RNA 
(Warashina et al, 2001). By this approach, genes that function in the Fas-mediated 
and tumor necrosis factor a mediated apoptosis pathway were identified (Kawasaki 
and Taira 2002; Kawasaki et al, 2002). These reports provide us implication that the 
design of a RNA helicase associated riboymes may help to disrupt gene expression. 
Future work 
In our study, all RNA tools failed to suppress gene expression of Elfm. One of the 
reasons may be the target site was not responsive to the RNA tools. We will try 
another strategy to study the gene silencing effect of Elfm by the ribozyme, such that 
a few more, say 6 to 9，in vitro active anti-Elfm ribozymes which target to different 
positions of Elfm mRNA are constructed. This strategy is known as "one-to-many" 
strategy, as besides other RNA tools, only ribozyme (one) is used to suppress gene 
expression by targeting to different positions (many). This strategy contrasts the 
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current strategy in this project, which is "many to one", different RNA tools (many) 
target to only a particular position (one). The advantage of adopting "one to many" 
strategy is that it can screen which sequence positions are responsive to the RNA 
tools. The success of the "one-to-many" strategy relies on the availability of a 
high-throughput screening system. It highlights the importance of an in vivo 
screening system for ribozymes. Based on the anti-GFP ribozymes we constructed in 
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The length of ORF of GFP is 717bp. The underlined region shows the cleavage site by 
the anti-GFP ribozymes. 
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The length of ORF of Elfm is 978bp. The underlined region shows the targeting site of 
the RNA tools, while the bolded site shows the cleavage site by the anti-Elfm ribozymes 
116 
Primer Sequence of chapter 3 
GFPinf: the forward primer that for GFP PGR amplification for in vitro transcription 
such that a T7 promoter was introduced as underlined. 
5 ' -CGAAATTAATACGACTCACTATAGATGGCTAGCAAAGGAGAA 
GFPinr: the reverse primer that for GFP PGR amplification for in vitro transcription 
such that the 2 inherent stop codon of GFP was included. 
5 ' -TATGCACACGTGGTGTCGAATTCATTATTTGTAGAG 
p3dRzf: the forward primer that for ribozyme amplification from pET-Rz in system a , 
the primer amplify an inherent Bglll site of pET3d. 5'-
TTCGCGAGATCTCGATCCCGCGAA 
p3dRzr: the reverse primer that for ribozyme amplification from pET-Rz in system a . It 
possessed a Bglll restriction site (underlined) for cloning and a pUC/M13 Reverse 
(17mer) for sequencing. 
5 ' -TTCGCGAGATCTTCCAGGAAACAGCTATGACGGATATCCGGATATAGTT" 
GFPneuf: the forward primer that for GFP PGR amplification for cloning into pET-neu 
in system p, 6 and co. A Dralll site (underlined region) was introduced upstream of the 
ORF. 5，-TATGCACACCACGTGATGGCTAGCAAAGGAGAAGAA 
GFPneur: the reverse primer that for GFP PGR amplification for cloning into pET-neu in 
system p, 6 and co. A DralU site (underlined) was introduced after the 2 inherent stop 
codons. 5 ' -TATGCACACGTGGTGTCGAATTCATTATTTGTAGAG 
p3dRzX: the forward primer that for ribozyme amplification from pET-Rz for cloning 
into pET-fhGFP in system 6. The Xbal site of the ribozymes was underlined. 
5 ' -TTCGCGAGATCTCGATCCCGCGAA 
p3dRzK: the forward primer that for riboyzme amplification from pET-Rz for cloning 
into pET-fhGFP in system co. A Kpnl restriction site was underlined. 
5 ’-TATGC AGGTACCCC AC AACGGTTTCCC 
p3dRzA: the reverse primer that for ribozyme amplification from pET-Rz for cloning 
into pET-fhGFP in system 6 and co. An Aflll restriction site was introduced as 
underlined. 
5’-TATGCACTTAAGTTAGCAGCCGGATCC 
GProf l : the forward primer that for Northern blot probe preparation, with a T7 promoter 
sequence as underlined for DIG labeling by transcription. 
5 ' -CGAAATTAATACGACTCACTATAGGAAAGATATAGTGCGTTC 
GProrl : the reverse primer that for Northern blot probe preparation 5'-
ATGGCTAGCAAAGGAGAA 
117 
GProf2: the forward primer that for Northern blot probe preparation, with a T7 promoter 
sequence as underlined for DIG labeling by transcription. 
5 '-CGAAATTAATACGACTCACTATAGTCATTATTTGTAGAGCTC 
GPror2: the reverse primer that for Northern blot probe preparation 5，-
ATGGAAACATTCTCGGAC 
Primer sequence in Chapter 4 
Neof: the forward primer that for the cloning of a neomycin resistance marker into 
pSilencer-R, a Dra l l l site was shown as underlined. 5，-
TATGCACACTACGTGGAGCTGATTTAACAAATA 
Neor: the reverse primer that for the cloning of a neomycin resistance marker into 
pSilencer-R, a Dralll site was shown as underlined. 5’-
TATGCACACGTAGTGATCCTTATCGCTATCGAT 
Elfinf: the forward primer that for the RT-PCR detection of Elfm expression level 
5'-TAGGCCGAATTCGATTGTGCCTAGCGATGACCACC 
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